KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Curent Deferred Tax Liability: 2014-2015

Historic Curent Deferred Tax Liability for Alnylam Pharmaceuticals (ALNY) over the last 1 years, with Sep 2015 value amounting to $9.4 million.

  • Alnylam Pharmaceuticals' Curent Deferred Tax Liability was N/A to $9.4 million in Q3 2015 from the same period last year, while for Sep 2015 it was $9.4 million, marking a year-over-year change of. This contributed to the annual value of $31.7 million for FY2014, which is N/A change from last year.
  • Alnylam Pharmaceuticals' Curent Deferred Tax Liability amounted to $9.4 million in Q3 2015, which was down 52.14% from $19.7 million recorded in Q2 2015.
  • In the past 5 years, Alnylam Pharmaceuticals' Curent Deferred Tax Liability registered a high of $33.7 million during Q1 2015, and its lowest value of $9.4 million during Q3 2015.
  • For the 2-year period, Alnylam Pharmaceuticals' Curent Deferred Tax Liability averaged around $23.6 million, with its median value being $25.7 million (2014).